In childhood acute lymphoblastic leukemia (ALL) about 70% of the patients can be cured with conventional chemotherapy. Despite new chemotherapy strategies, about 30% suffer a relapse. Major approaches for early identification of these patients are: (1) initial features at presentation of the disease (age, leukocyte count, immunophenotype, chromosomal translocations like t(9;22) or t(4;11)); (2) in vivo or in vitro response to chemotherapy or, as recently established: (3) the identification of risk groups via the measurement of minimal residual disease (MRD) during the first 3-5 months of therapy. [1] [2] [3] The threshold for predicting relapse depended on the time-point of detection: a high leukemic load of у10 −2 residual cells at the end of induction multiplied the risk about 10-fold, about 10 −3 distinguished good and poor risk patients at later time-points (eg after 12-15 weeks of therapy). Patients with a high MRD level might benefit from different treatment strategies or bone marrow transplantation. In addition a good molecular responder may be sufficiently treated with a reduced therapeutic regimen.
PCR-based analysis of MRD allows the detection of residual leukemic cells down to a level of 10 −5 . Due to a high prevalence in B cell precursor (BCP) and T cell leukemias (T-ALL) clonal T cell receptor (TCR) or immunoglobulin heavy or light chain (IgH/IgL) rearrangements were the most suitable targets. 4, 5 Patient-specific junctional region sequences served as clone-specific markers in each patient sample.
Within two COALL studies initiated in 1992 and 1997, 6 bone marrow samples were collected at the end of induction therapy. In brief, therapy consisted of a 1-week prephase with daunorubicin (24 h continuous infusion on day 1) and intrathecal methotrexate. Induction therapy started with three drugs given over a period of 4 weeks (prednisolone, vincristine and daunorubicin). After completion of this treatment (day 36), bone marrow samples were taken for MRD analysis and therapy was continued. After diagnosis, patients were stratified into two risk groups: The low risk group consisted of patients with leukocytes less than 25 × 10 3 /l and C-ALL/preB-ALL and age Ͼ1 or Ͻ10 years. The high risk group consisted of patients with leukocytes у25 × 10 3 /l or pro-B/T-ALL or age у10 years. The above-mentioned patient populations were the target group for our MRD studies. Very high risk patients with translocations t(9;22) or t(4;11) or no remission at day 36 were excluded from MRD analysis. Until now, patients were only selected for the availability of bone marrow mononuclear cells and were comparable to the 521 patients enrolled in the COALL 92 study. T-ALL patients were slightly overrepresented (20% in the MRD group vs 15% in the whole group).
All 76 patients analyzed were in clinical remission at the end of induction therapy. After induction therapy, 43 patients (57%) were treated according to the COALL high risk and 33 patients (43%) to the low risk chemotherapy protocol. Fifteen patients had T-ALL, 10 pre-B-ALL and 51 C-ALL. Clinical samples (bone marrow or peripheral blood from diagnosis and bone marrow from the end of induction) were collected during trials COALL 92 and 97. Ficoll-separated cells were frozen in 10% DMSO/50% FCS/RPMI 1640 and stored at −80°C until use. DNA was isolated using the High Pure PCR Template Preparation Kit (Roche Molecular Diagnostics, Mannheim, Germany).
PCR targets for detection of MRD were identified from initial leukemic DNA using a standard set of primers for TCR ␥, ␦, Kde 4 and the IgH family specific primer set described by Deane and Norton. 5 Monoclonal bands were either sequenced directly or after excision from agarose gels (ABI 377 with dye terminators, PE Biosystems, Weiterstadt, Germany). Based on the obtained sequence data, allele specific oligonucleotide (ASO)-PCR primers were designed spanning the junctional region of the patient specific rearrangement including a 3Ј overlap complementary to 2-4 bases of the constant region sequences.
For MRD analysis, first PCR was performed using 1 g DNA, 2 U Taq polymerase (Roche Molecular Diagnostics) in a 50 l reaction (standard PCR buffer with 1.5 mm MgCl 2 , 200 m each dNTP and 200 nm each primer). Samples were subjected to an initial 5 min 95°C denaturation step followed by 35 cycles at 95°C (30 s), 56-60°C (annealing depending on the primer set used for 30 s) and 72°C for 30-45 s in a thermocycler (Trio-block; Biometra, Goettingen, Germany) using thin walled PCR tubes (Biozym, Hess, Oldendorf, Germany). Products were visualized after agarose gel electrophoresis and ethidium bromide staining. After successful amplification of the first round nested PCR was performed with 3-5 l of a 100-fold dilution in H 2 O. A 50 l reaction was performed with 15-25 cycles and patient-specific primers.
Sensitivity was evaluated by a serial 10-fold dilution of initial leukemic DNA in DNA from healthy donors. Samples were only selected for analysis after successful amplification of first and second round PCR. All clinical relevant follow-up samples from the end of induction therapy were amplified in duplicate and parallel to the serial dilutions within one 'master mix'. The amplification rate of the patients' follow-up samples were compared to the serial dilutions with a semiquantitative estimation described by van Dongen and colleagues: 2 у10 Figure 1 illustrates the detection of residual disease using the nested PCR approach in four cases with different levels of MRD. Fifteen patients with T-ALL were monitored for MRD. At the molecular level all patients with T-ALL had detectable residual disease. Nine of them revealed a high positive signal (у10 −2 ) and six were less than 10 −2 positive. All relapses within T-ALL occurred in the high level group (three relapses within 336, 456 and 549 days after diagnosis). Table 1 shows the distinct MRD level compared to the immunologic subtype of the leukemia. Of 61 BCP-ALL 10 were у10 −2 positive (see Table 1 ). Two of these patients relapsed and one patient received bone marrow transplantation due to a high in vitro resistance score. 6 Three intermediate level MRD positive BCP-ALL patients suffered a relapse (2/4 Pre-B-ALL and 2/19 patients with C-ALL). In one patient with low MRD at the end of induction a relapse occurred 973 days after diagnosis. In . All ASO-PCR reactions were performed with 15-20 cycles to achieve a most informative 'end of induction' sample. (2) 13 (1) 11 3 (n), the number of relapses in the distinct subgroups.
summary, patients with a very high MRD load still have a probability of disease-free survival of 70% (Figure 2 ). From our results it seems that a high level of MRD at the end of induction therapy is not necessarily associated with a high probability of relapse. Only 5/20 patients with high level MRD (у10 −2 ) relapsed in our study. These findings are in contrast to several other published data: Cave and colleagues 1 analyzed the MRD level at the end of induction therapy from 133 children with ALL, 15 were positive on a high level (у10 −2 ). Eleven of them suffered a relapse (73%). Van Dongen and colleagues 2 analyzed 169 patients at the end of induction, 27 had high level MRD (у10 −2 ) and 20 (74%) of these patients relapsed.
In our study residual disease was detected in 65/76 patients available for MRD analysis at the end of induction therapy. Only 12 negative patients were found (16%). Compared to other studies these findings are surprising. Van Dongen and colleagues found 71/169 (42%) and Cave et al 58% MRD negative patients (see Figure 3) .
One explanation for this discrepancy may be the different induction therapy given in the different studies. Induction therapy in the BFM study as well as in the French study group (with a BFM-related protocol) consisted of a four-drug regimen (PRED, VCR, DNR and L-ASP) including a 1-week prednisolone prephase with i.t. MTX. The COALL protocols used in this study started therapy with one dose of daunorubicin and i.t. MTX followed by a three-drug regimen including PRED, VCR, DNR. Asparaginase is given during the intensified therapy subsequently. This slightly reduced induction therapy may
Figure 2
Life table analysis of relapse-free survival according to the MRD level at the end of induction therapy. Seventy-six patient samples from 15 T-ALL and 61 B-lineage ALL were included. Outcome of patients with MRD level у10 −2 was compared to a level of less than 10 −2
. Significance was observed with P = 0.0052. Median time on risk (MOR) was 1.63 years for the MRD group у10 −2 and 3.98 years for the other group. All events before 01.09.1999 were included in the disease-free analysis.
Figure 3
MRD at the end of induction therapy. The presented COALL study data after induction therapy were compared to the German BFM study, the French/Belgium EORTC study and to a MRD study from St Jude's. VCR, vincristine; DNR, daunorubicin; PRED, prednisolone; L-ASP, asparaginase; VM-26, teniposide; ARA-C, cytarabine.
result into a higher leukemic load on day 36. Thus, differences in MRD levels between these two groups may result from the omission of asparaginase, which is given later in our therapy. The results of Gruhn et al 7 point in the same direction. In a small number of BCP-ALL patients their intensive six-drug regimen resulted in a 73% MRD negativity. Thus a six-drug induction protocol is even more effective in eradicating leukemic cells on MRD level. Gruhn et al also suggest that the optimal sampling pattern for MRD depends on the therapeutic schedule.
As there is no major difference in the event-free survival of COALL 92 and BFM 90 studies, the less intensive therapy upfront may be compensated for within the following weeks of therapy. Therefore we conclude from our results, that high MRD levels (у10 −2 ) at the end of induction therapy are not necessarily associated with a poorer prognosis. The discriminatory power after induction therapy is strongly associated with the given chemotherapy. In our study, detection of residual disease may be more informative and predictive at later time-points. These time-points have to be evaluated for each study before stratification according to MRD levels can be performed.
